Company Overview
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage biotechnology company dedicated to the development of small-molecule therapeutics that target upstream biological drivers of aging and age-related diseases. The company focuses on creating specific oral small molecule metal ion regulators, such as Telomir-1, which are designed to address fundamental biological mechanisms rather than just symptoms of aging. This entity functions within the broader healthcare sector and specifically the biotechnology industry, where the primary business model involves extensive research and development before products reach commercialization. With a market capitalization of $42.98M and an annual revenue figure that is not disclosed in the available data, the company operates on a micro-cap scale relative to large-cap pharmaceutical peers. The absence of reported annual revenue and the preclinical nature of its pipeline indicate that the company is currently in a capital-intensive phase where cash reserves are being utilized to fund development rather than generating sales, positioning it as a high-risk, high-potential venture focused on long-term therapeutic breakthroughs.
Financial Health
The company reports a net income of $-10,413,205 for the trailing twelve months, while both revenue and EBITDA are listed as unavailable or effectively zero in the current reporting period. The significant gap between reported revenue (which is N/A) and the substantial net loss reveals a cost structure dominated by research and development expenses that far exceed any current revenue generation. Free cash flow stands at $-86,566, indicating that the company is currently burning cash to sustain its operations and advance its clinical pipeline rather than generating liquidity from business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the early-stage nature of the business where costs are incurred without corresponding revenue to generate profitability. On the balance sheet, the company holds $7.29M in cash against total debt of $473,752, resulting in a debt-to-equity ratio of 8.01 which suggests a highly leveraged position relative to its equity base. Despite the high debt-to-equity figure, the current ratio of 5.14 indicates robust short-term liquidity, as the company possesses more than five times the current assets necessary to cover its current liabilities. Return on Equity is -317.6% and Return on Assets is -152.0%, metrics that reveal management is currently diluting shareholder value and utilizing assets to generate losses typical of preclinical biotechnology firms.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of net income, while the forward P/E is listed as -4.46, a negative figure that implies the market expects continued losses or that earnings are not yet positive enough to support a traditional valuation multiple. The price-to-book ratio stands at 7.27, indicating that the market values the company at a significant premium over its book value, a common scenario for biotechnology firms where the value of intellectual property and pipeline potential exceeds the tangible assets recorded on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unavailable or not applicable, suggesting that standard valuation models relying on sales multiples or enterprise value multiples cannot be effectively applied to this preclinical-stage entity. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $1.05 and a 52-week high of $4.80. Without a specific current price provided in the facts, the valuation context suggests the stock is sensitive to clinical trial updates and regulatory news given its position within the trading range. The beta value of -0.65 indicates an inverse correlation to the broader market, meaning the stock tends to move in the opposite direction of the market index, introducing unique non-market risks to its price trajectory.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which is consistent with the company's preclinical status where historical growth metrics are not yet established. Because the company is not yet generating significant revenue, there is no data to determine whether earnings are growing faster or slower than revenue, but the current negative net income indicates that the business is not yet profitable. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available earnings—or rather, all available cash reserves—into research and development efforts to advance its drug candidates. This growth profile is characteristic of biotechnology startups that prioritize expanding their pipeline and securing regulatory approvals over returning capital to shareholders in the form of dividends. The overall growth and income profile is defined by a complete reliance on external financing and internal cash reserves to fund operations, with no current contribution to shareholder income through dividends or earnings growth.